Stock ARVN ARVINAS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Arvinas, Inc.

Equities

ARVN

US04335A1051

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
32.37 USD +2.44% Intraday chart for Arvinas, Inc. -6.77% -21.36%
04-24 Arvinas, Inc. Appoints Randy Teel as Chief Business Officer CI
04-15 H.C. Wainwright Cuts Price Target on Arvinas to $87 From $90, Maintains Buy Rating MT

Business Summary

Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.

Number of employees: 445

Sales per Business

USD in Million2022Weight2023Weight Delta
Protein Degradation Therapeutics
100.0 %
131 100.0 % 79 100.0 % -40.26%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
131 100.0 % 79 100.0 % -40.26%

Managers

Managers TitleAgeSince
John Houston CEO
 Chief Executive Officer 64 31/12/16
Randy Teel DFI
 Director of Finance/CFO 45 30/04/18
Lisa Sinclair COO
 Chief Operating Officer - 14/08/22
John Grosso CTO
 Chief Tech/Sci/R&D Officer - -
Ian Taylor CTO
 Chief Tech/Sci/R&D Officer 61 31/12/15
Kimberly Wehger CTO
 Chief Tech/Sci/R&D Officer - -
Jeff Boyle IRC
 Investor Relations Contact - 31/08/21
Paul McInulty LAW
 General Counsel - 02/10/22
Jared M. Freedberg LAW
 General Counsel 55 01-15
Steve Weiss HRO
 Human Resources Officer 55 28/02/18

Members of the board

Members of the board TitleAgeSince
Wendy Dixon BRD
 Director/Board Member 68 28/06/20
John Young BRD
 Director/Board Member 60 17/08/22
Leslie Norwalk BRD
 Director/Board Member 58 23/07/19
Briggs Morrison BRD
 Director/Board Member 65 31/05/18
Laurie Alsup BRD
 Director/Board Member 70 19/11/19
Edward Kennedy BRD
 Director/Board Member 62 30/06/18
Sunil Agarwal BRD
 Director/Board Member 54 14/06/23
Everett Cunningham BRD
 Director/Board Member 57 15/12/22
Linda Bain BRD
 Director/Board Member 53 09/06/20
John Houston CEO
 Chief Executive Officer 64 31/12/16

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 68,308,405 66,211,150 ( 96.93 %) 0 96.93 %

Shareholders

NameEquities%Valuation
EcoR1 Capital, LLC
9.880 %
6,726,491 9.880 % 278 M $
BlackRock Advisors LLC
7.318 %
4,982,190 7.318 % 206 M $
Vanguard Fiduciary Trust Co.
7.126 %
4,851,390 7.126 % 200 M $
RTW Investments LP
6.189 %
4,213,483 6.189 % 174 M $
T. Rowe Price International Ltd.
5.629 %
3,832,123 5.629 % 158 M $
PFIZER, INC.
5.079 %
3,457,815 5.079 % 143 M $
Avidity Partners Management LP
4.384 %
2,985,117 4.384 % 123 M $
Bellevue Asset Management AG
3.683 %
2,507,731 3.683 % 104 M $
Citadel Securities GP LLC
3.584 %
2,439,981 3.584 % 101 M $
Fidelity Management & Research Co. LLC
3.296 %
2,244,019 3.296 % 93 M $

Company contact information

Arvinas, Inc.

5 Science Park 395 Winchester Avenue

06511, New Haven

+

http://www.arvinas.com
address Arvinas, Inc.(ARVN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Arvinas, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
32.37 USD
Average target price
70.83 USD
Spread / Average Target
+118.82%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ARVINAS, INC. Stock Arvinas, Inc.
-21.36% 2.21B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ARVN Stock
  4. Company Arvinas, Inc.